1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization
Key populations brief
Accessed November 2017
Overcoming HIV-related stigma and discrimination in health- care settings and beyond
UNAIDS 2017 | REFERENCE
Blueprint for EECA countries, first edition
Guidance on Implending Publi-Private Mix Approaches
Guidelines for national programmes and other stakeholders, for annexes see http://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/
Lessons from the STEP-TB Project.
Accessed November 2017.
WHO Information Leaflet COVID-19: Considerations on tuberculosis (TB) care